UNITED STATES
                        SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C. 20549
                                    FORM 10-KSB

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934 For the fiscal year ended December 31, 2003

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
    EXCHANGE ACT OF 1934

    For the transition period from to .

                         Commission File Number: 000-31735

                              NANOSIGNAL CORPORATION
                     (Name of Small Business Issuer in its charter)


        Nevada                                          88-0231200
 (State or other jurisdiction of                      (IRS Employer
 incorporation or organization)                      Identification Number)

                            5440 W Sahara Ave, Suite 206
                       (Address of principal executive offices)

                              Las Vegas, NV  89146
                              (City, State and Zip Code)

                                    (702) 227-5111
                   Company's telephone number, including area code


      Securities registered pursuant to Section 12(b) of the Act: None.

                Name of each exchange on which registered: None.

   Securities registered pursuant to Section 12(g) of the Act: Common Stock

Check whether the Issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or
such shorter period of that the Registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past
90 days.    Yes    X No

Check if there is no disclosure of delinquent filers to Item 405 of
Regulation S-B contained in this form, and if no disclosure will be
contained, to the best of the Registrants knowledge, in definitive proxy
or information statements incorporated by reference in Part III of this
Form 10-K. [ ]

State Issuer's Revenues for its most recent fiscal year: $0

The number of shares outstanding of the Company's $.001 Par Value Common
Stock,as of December 31, 2003 were 123,323,714.  The aggregate number of
shares of the voting stock held by non-affiliates on December 31, 2003 was
37,146,745. The market value of these shares, computed by reference to the
market closing price on December 31, 2003 was $8,172,283. For the purposes of
the foregoing calculation only, all directors and executive officers of the
registrant have been deemed affiliates.

                 DOCUMENTS INCORPORATED BY REFERENCE: None.

<PAGE>

                                   PART I

ITEM 1. BUSINESS

A) General

MicroSignal Corporation (the "Company) was incorporated on August 21, 1987 as
"Ragen Corporation" under the laws of the State of Nevada. On October 21,
1999, the Company entered into a reverse merger pursuant to Rule
368(a)(1)(B)if the Internal Revenue Code of 1986 as amended. Pursuant to this
reverse merger, the Company acquired 100% of the common stock of Pro Glass
Technologies, Inc., a Canadian corporation with three wholly owned
subsidiaries in exchange for the issuance of 17,714,000 shares of the
Company's common stock. The Company changed its name to "Pro Glass
Technologies, Inc." and increased the number of authorized common shares to
50,000,000 at that time. Pro Glass Technologies, Inc. is the predecessor due
to the reverse merger and Ragen was the legal survivor. Pro Glass
Technologies, Inc. was a holding company.

Upon completion of the merger, the Company began engaging in the auto glass
repair and replacement business under "Windshield Superstores, Ltd." in
Calgary, Alberta. Fran Aiello became the President and CEO of the Company at
that time.

On September 10, 2002, the Company entered into an Agreement and Plan of
reorganization with MicroSignal Corporation, a Pennsylvania corporation, and
exchanged 100% of the MicroSignal common stock in exchange for the issuance
of 17,051,344 shares of the Company's common stock, or 94% of the Company.
At that time, the Company changed its name to "MicroSignal Corporation".  At
the same time, the Company sold its auto glass repair and replacement
business to its former president, Frank Aiello, in change for the return of
150,000 shares of the Company's common stock owned by him. Mr. Aiello assumed
responsibility for all the debts and liabilities of the auto glass repair and
replacement business. For accounting purposes, this transaction was treated
as an acquisition of Pro Glass and a recapitalization of MicroSignal,
MicroSignal is the accounting acquirer and the results of its operations
carry over. Accordingly, the operations of the Company while Pro Glass are
not carried over and are adjusted to $0. As part of this transaction, the
Company's fiscal year end changed from September 30 to December 31.

The Company has developed a product designed to improve the quality and
efficiency of magnetic resonance imaging ("MRI") systems. The product
consists of a combination of hardware and software compatible with all MR
machines, designed to improve the image quality as well as the display of the
final MRI exam. At the core of the system is a totally novel method of
reconstructing the MR information obtained by the machine (the raw data),
developed by Dr. Jeffery Taft. The Company's product uses a unique algorithm,
exchange analytic computation technique (EXACT), which decouples the size of
the raw data from the image matrix size and overcomes a lot of the inherent
limitations of the Fourier transformations.  The technology allows tremendous
flexibility once the MRI data has been acquired; it is possible using
SLICES(TM) to obtain sharply magnified images, up to ten times the original
magnification, without creating pixel artifacts inherent to the optical zoom
provided by all manufacturers. The major benefits of MSC's SLICES technology
are:

Increased information extraction Helps with the elimination of some artifacts
Improves the radiologist's productivity Reduces patient re-scan and call back
Reduces patient scan time
Reduces film costs

The Company intends to proceed with marketing and sales of the Company's
proprietary product.

<PAGE>

Significant opportunities exist for follow-on product both in MRI and in
other computed medical imaging applications such as CAT scan and
nuclear medicine. Exciting opportunities exist to apply new proprietary
MicroSignal Corporation technology to stroke prediction, breast cancer
detection and cardiac evaluation, thus expanding MRI into use for the top
three disease conditions in the U.S. Sales opportunities for these
additional products are in the billions of dollars.

Additional opportunities exist to make use of the Internet to perform high-
end teleradiology and Picture Archiving and Control. MicroSignal
Corporation can become the preferred channel not only for computing and
displaying medical images, but also for transporting them. The transport, if
done properly, can result in an ongoing revenue stream valued in the hundreds
of millions of dollars per year within five years.  There can be no
assurances that the Company will see these results. Future revenues are
dependent upon the Company being able to secure outside financing and raising
additional capital to enable it to commence operations in a meaningful
manner, neither of which the Company has commitments to receive. Until such
time as the Company is able to secure additional financing through loans or
capital raising, the Company's efforts to commence revenue producing
operations will have to be scaled back.

The Company's office is located at 5440 W Sahara Ave, Suite 206, Las Vegas,
 NV 89146.

As of December 31, 2003 the Company had three employees.

Item 2. Properties.

The Company presently leases office space on a three-month rental agreement,
which ends in March 31, 2004. The monthly lease payment is $891.00.  The
Company anticipates that this space is sufficient for the near future.

Item 3 Legal Proceedings.

The Company was awarded a favorable ruling in a lawsuit brought about by
shareholders.  This ruling was appealed and the company reached a settlement
agreement with the parties on April 6, 2004.

Item 4. Submission of Matters to a Vote of Security Holders

In March 2004, the Company's shareholders approved a change of name to
"NanoSignal Corporation" and increased the authorized shares of common stock
to 500,000,000.

Item 5. Market for Registrant's Common Equity and Related Shareholder
Matters.

The Company's common stock is traded on the OTC Electronic Bulletin Board
under the symbol "NNSO". Quotations in the Company's common stock set forth
below do not constitute a reliable indication of the price that a holder of
the common stock could expect to receive upon the sale of any particular
quantity thereof.

The following table reflects the range of high and low quarterly bid prices
for the fiscal year ended December 31, 2003 This information was provided to
the Company by the National Association of Securities Dealers, Inc. (the
"NASD"). These quotations reflect inter-dealer prices, without retail mark-up
or markdown or commissions. These quotations may not necessarily reflect
actual transactions.


-------------------- -------------------- --------------------
Period               High Bid             Low Bid
-------------------- -------------------- --------------------
1st Qtr 2003        .10                  .06
--------------- --------------- ---------------
2nd Qtr 2003        .34.                 .14
-------------------- -------------------- --------------------
3rd Qtr 2003        .18                  .02
-------------------- -------------------- --------------------
4th Qtr 2003        .28                  .06
-------------------- -------------------- --------------------
<PAGE>

As of December 31, 2003 the Company had 122,323,714 shares of its common
stock issued and outstanding, of which 37,146,745 were held by non-
affiliates.

As of December 31, 2003, the Company estimates there are 113 "holders of
record" of its common stock which figure does not take into account those
shareholders whose certificates are held in the name of broker-dealers. In
March 2004, the Company's Board of Directors approved a proposal to
increase the Company's capitalization to 500,000,000 shares of common stock,
which proposal was subsequently approved by the Company's shareholders.

Recent Sales of Securities

During 2003, the Company issued a total of 73,234,534 shares of the
Company's common stock, to consultants for services rendered.

Dividend Policy

The Company has not declared nor paid cash dividends or made distributions in
the past, and the Company does not anticipate that it will pay cash dividends
or make distributions in the foreseeable future. The Company currently
intends to retain and reinvest future earnings, if any, to finance and expand
its operations.

Item 6. Management's Discussion and Analysis or Plan of Operation.

FORWARD-LOOKING STATEMENTS MAY NOT PROVE ACCURATE

When used in this Form 10-KSB, the words "anticipated", "estimate", "expect",
and similar expressions are intended to identify forward-looking statements.
Such statements are subject to certain risks, uncertainties and assumptions
including the possibility that the Company's will fail to generate projected
revenues. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, estimated or projected.

The following discussion should be read in conjunction with the financial
statements and notes thereto appearing elsewhere in this Form 10-KSB.

Plan of Operation

In connection with the Company's acquisition of MicroSignal Corporation, the
Company acquired technology used to enhance MRI imaging. The Company has
developed a product designed to improve the quality and efficiency of
magnetic resonance imaging ("MRI") systems. The product consists of a
combination of hardware and software compatible with all MR machines,
designed to improve the image quality as well as the display of the final MRI
exam. At the core of the system is a totally novel method of reconstructing
the MR information obtained by the machine (the raw data), developed by
Dr. Jeffery Taft. The Company's product uses a unique algorithm, exchange
analytic computation technique (EXACT), which decouples the size of the raw
data from the image matrix size and overcomes a lot of the inherent
limitations of the Fourier transformations. The technology allows tremendous
flexibility once the MRI data has been acquired; it is possible using SLICES
to obtain sharply magnified images, up to ten times the original
magnification, without creating pixel artifacts inherent to the optical zoom
provided by all manufacturers.

The Company plans to seek financing and capital to allow it to exploit this
technology as well as to enhance and improve on this technology. During 2004,
the Company intends to seek the necessary financing to allow it to implement
its business plan and to commence operations in a meaningful way.

<PAGE>

In connection with the MicroSignal acquisition, the Company sold its auto
glass repair and replacement business to its former President in exchange for
the return of stock as well as assumption of all liabilities of the auto
glass operations.

Liquidity and Capital Resources
The Company has approximately $46,388 in current assets compared to current
assets of approximately $2,000 for the year ended December 31, 2002. The
Company's current liabilities for the year ended December 31, 2003 are
approximately $3,947,676 compared to current liabilities of approximately
$3,000,000 for the year ended December 31, 2002. The difference in assets and
liabilities are related to the Company's acquisition of the MRI imaging
business and its sale of the auto glass business. The current assets for the
year ended December 31, 2003 consisted of cash of $46,388. Total assets were
approximately $67,582 for the year ended December 31, 2003 composed of the
Company's property and equity of 21,194 and
its cash.

At December 31, 2003, the Company had negative working capital of
approximately ($3,901,288) which consisted of current assets of
approximately $46,388 and current liabilities of approximately $3,947,676. At
December 31, 2002, the Company had working capital of approximately
($2,958,964) which consisted of current assets of approximately $1,967 assets
and current liabilities of approximately ($2,960,931). The current liabilities
of the Company at December 31, 2002 are composed primarily of notes payable to
shareholders of $1,361,750, notes payable of $615,339, accrued interest
payable of $755,700, accrued expenses of $138,292, lease payable of $38,650,
deposits of $40,000 and accounts payable of $11,000.

Net Operating Losses

The Company has accumulated net operating losses since inception, which may
be used to reduce taxes in future years. The use of these losses to reduce
future income taxes will depend on the generation of sufficient taxable
income prior to expiration of the net operating loss carryforwards.

In the event of certain changes in control of the Company, there will be an
annual limitation on the amount of net operating loses carryforwards which
can be used. The potential tax benefit of the net operating loss
carryforwards have been offset by a valuation allowance of the same amount.

Results of Operations

The following discussion of the financial condition, changes in financial
condition and results of operations of the Company for the fiscal years
ended December 31, 2003 and December 31, 2002 should be read in conjunction
with the financial statements of the Company and related notes included
therein.

For the years ended December 31, 2003 and 2002, the Company had no revenue.
For the year ended December 31, 2003, the Company had operating expenses of
approximately $13,593,541 compared to operating expenses of approximately
$397,117 at December 31, 2002. The Company's expenses consisted primarily
of consulting Costs, impairment and general and administrative expenses. The
net loss for the year ended December 31, 2003 was approximately ($13,773,044)
or ($.25) pershare of common stock compared to the net loss for the ended
December 31, 2002 of approximately ($549,893) or ($.04) per share of common
stock.

At December 31, 2003, shareholders' equity was a deficit of approximately
($18,657,460).

The Company will attempt to carry out its business plan as discussed above.
The Company cannot predict to what extent its lack of liquidity and capital
resources will hinder its business plan prior to commencement of its proposed
operations.

<PAGE>

Need for Additional Financing

The Company's existing capital is not be sufficient to meet the Company's
cash needs, including the costs of compliance with the continuing
reporting requirements of the Securities Exchange Act of 1934, as amended.

No commitments to provide additional funds have been made by management or
other stockholders. Accordingly, there can be no assurance that any funds
will be available to the Company to allow it to cover its expenses.

The Company might seek to compensate providers of services by issuances of
stock in lieu of cash.

Effect of Inflation

Inflation did not have any significant effect on the operations of the
Company during the year ended December 31, 2003. Further, inflation is
not expected to have any significant effect on future operations of the
Company.

Item 7. Financial Statements.

Financial statements are audited and included herein beginning on Exhibit 1,
page 1 and are incorporated herein by this reference.

Item 8. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.

There were no disagreements with accountants on accounting and financial
disclosure during the relevant period.

                               Part III

Item 9. Directors, Executive Officers, Promoters and Control Persons;
Compliance with Section 16(a) of the Exchange Act.

Identification of Directors and Executive Officers of the Company

The following table sets forth the names and ages of all directors and
executive officers of the Company and all persons nominated or chosen to
become a director, indicating all positions and offices with the Company held
by each such person and the period during which he has served as a director:

The principal executive officers and directors of the Company are as follows:

       Name                               Positions Held and Tenure

  Dr. Lawrence Madoff       President, CFO and Director since December 2003

  Dr. Rupert Perrin         Director since December 2003


The Directors named above will serve until the next annual meeting of the
Company's stockholders. Thereafter, Directors will be elected for one-year
terms at the annual stockholders' meeting. Officers will hold their positions
at the pleasure of the Board of Directors, absent any employment agreement,
of which none currently exist or is contemplated. There is no arrangement or
understanding between the Directors and Officers of the Company and any other
person pursuant to which any Director or Officer was or is to be selected as
a Director or Officer of the Company.

There is no family relationship between or among any Officer and Director.

The Directors and Officers of the Company will devote their time to the
Company's affairs on an "as needed" basis. As a result, the actual amount of
time which each will devote to the Company's affairs is unknown and is likely
to vary substantially from month to month.

The Company has no audit or compensation committee.

<PAGE>

Business Experience. The following is a brief account of the business
experience during at the least the last five years of the directors and
executive officers, indicating their principal occupations and employment
during that period, and the names and principal businesses of the
organizations in which such occupations and employment were carried out.

Dr. Larence Madoff. Dr. Madoff was appointed president CFO of the Company in
December 2003.


CONFLICTS OF INTEREST

The outside Director of the Company will devote only a small portion of their
time to the affairs of the Company, estimated to be no more than
approximately 5 hours per month. There will be occasions when the time
requirements of the Company's business conflict with the demands of their
other business and investment activities. Such conflicts may require that the
Company attempt to employ additional personnel. There is no assurance that
the services of such persons will be available or that they can be obtained
upon terms favorable to the Company. The sole officer and inside director
works for the Company on a full-time basis.

There is no procedure in place which would allow the Officers and Directors
to resolve potential conflicts in an arms-length fashion. Accordingly, they
will be required to use their discretion to resolve them in a manner which
they consider appropriate.

Identification of Certain Significant Employees. The Company has three
employee, its President, Dr. Lawrence Madoff, Dr. Rupert Perrin and Andrea
Lindsey. The Company does not employ any persons who make or are expected to
make significant contributions to the business of the Company other than
these individuals.

Item 10. Executive Compensation.

During fiscal 2003, and as of the date of the filing of this report, only the
Company's President, Dr. Rupert Perrin, Director and Andrea Linsey had been
paid any compensation by the Company.

Compensation of Directors

Directors are entitled to reimbursement for reasonable travel and other out-
of-pocket expenses incurred in connection with attendance at meeting of the
Board of Directors.

The Company has no material bonus or profit sharing plans pursuant to which
cash or non-cash compensation is or may be paid to the Company's directors or
executive officers except as described above.

The Company has no compensatory plan or arrangements, including payments to
be received from the Company, with respect to any executive officer or
director, where such plan or arrangement would result in any compensation or
remuneration being paid resulting from the resignation, retirement or any
other termination of such executive officer's employment or from a change-in-
control of the Company or a change in such executive officer's
responsibilities following a change-in-control and the amount, including all
periodic payments or installments where the value of such compensation or
remuneration exceeds $100,000 per executive officer.

During the last completed fiscal year, no funds were set aside or accrued by
the Company to provide pension, retirement or similar benefits for
Directors or Executive Officers.

<PAGE>

The Company has a written employment agreement with its President, Dr. Lawrence
Madoff, Director, Dr. Rupert Perrin and Secretary, Andrea Lindsey.

Compensation Pursuant to Plans. Other than disclosed above, the Company has
no plan pursuant to which cash or non-cash compensation was paid or
distributed during the last fiscal year, or is proposed to be paid or
distributed in the future, to the individuals and group described in this
item.

Compensation of Directors. Directors of the Company are entitled to
reasonable reimbursement for their travel expenses in attending meetings
of the Board of Directors.

Termination of Employment and Change of Control Arrangement. Except as noted
herein, the Company has no compensatory plan or arrangements, including
payments to be received from the Company, with respect to any individual
names above from the latest or next preceding fiscal year, if such plan or
arrangement results or will result from the resignation, retirement or any
other termination of such individuals employment with the Company, or from a
change in control of the Company or a change in the individuals
responsibilities following a change in control.

Section 16(a) Beneficial Ownership Reporting Compliance. During the year
ended December 31, 2002, the following persons were officers,
directors and more than ten-percent shareholders of the Company's common
stock:


Name                       Position                           Filed Reports

Dr. Lawrence Madoff          President, CFO                        No
Dr. Rupert Perrin            Director                              No
Andrea Lindsey               Director, President                   No

Item 11. Security Ownership of Certain Beneficial Owners and Management.

There were 122,323,714 shares of the Company's common stock issued and
outstanding on December 31, 2003. The following tabulates holdings of shares
of the Company by each person who, subject to the above, at the date of this
Report, holds or record or is known by Management to own beneficially more
than five percent (5%) of the Common Shares of the Company and, in addition,
by all directors and officers of the Company individually and as a group.


------------------------------- ---------------------.-----------------------
Name and Address                 Number of Shares     Percent of Beneficially
                                Owned Beneficially         Owned Shares
------------------------------- ---------------------.-----------------------
MicroSignal Corp.                  17,051.344                13.94%
345 Southpointe Blvd.
Canonsburg, PA 15317
------------------------------- ---------------------.-----------------------
GW Walters Group                   19,000,000                15.53%
BBX Equity Group                   18,000,000                14.71%
-----------------------------------------------------------------------------
All Directors and
Executive Officers                  8,475,000                 6.93%
as a Group (two persons)
------------------------------- ---------------------.-----------------------

* Denotes officer or director

Changes in Control. There are no arrangements known to the Company, including
any pledge by any person of securities of the Company, the operation of which
may at a subsequent date result in a change of control of the Company.

<PAGE>

Item 12. Certain Relationships and Related Transactions.

In September 2002, the Company issued 17,051,344 to the shareholders of

MicroSignal Corporation, a Pennsylvania corporation in connection with its
acquisition of MicroSignal. The president of MicroSignal became the
President, CEO and CFO as well as director of the Company in connection with
that transaction.

Item 13. Exhibits and Reports on Form 8-K.

(a) Financial Statements and Schedules

The following financial statements and schedules are filed as part of this
report:

Independent Auditors' Report dated
Balance Sheet for the Fiscal Years Ended December 31, 2003 Statement of
Operations for the Fiscal Years Ended December 31, 2003 and 2002 Statement of
Shareholders' Equity (Deficit) Statements of Cash Flows Notes to Financial
Statements




<PAGE>

                               INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
  NanoSignal Corporation
  (Formerly known as Microsignal Corporation)
  Las Vegas, Nevada

We have audited the accompanying balance sheet of NanoSignal Corporation
(Formerly known as MicroSignal Corporation) as of December 31, 2003, and the
related statements of expenses stockholders' equity (deficit), and cash flows
for each of the two years then ended.  These financial statements are the
responsibility of NanoSignal's management.  Our responsibility is to express
an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally
accepted in the United States of America.  Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement.  An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements.  An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation.  We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of NanoSignal Corporation as of
December 31, 2003, and the results of its operations and cash flows for each
of the two years then ended, in conformity with accounting principles
generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that
NanoSignal will continue as a going concern.  As discussed in Note 2 to the

financial statements, NanoSignal has incurred losses for the years ended
December 31, 2003 and 2002 totaling $13,773,044 and $549,893 and had negative
working capital of $3,901,288 as of December 31, 2003.  NanoSignal will
require additional working capital to develop and support its technologies
and business until NanoSignal either (1) achieves a level of revenues
adequate to generate sufficient cash flows from operations; or (2) obtains
additional financing necessary to support its working capital requirements.
These conditions raise substantial doubt about NanoSignal's ability to
continue as a going concern.  Management's plans in regard to this matter are
also described in Note 2.  The accompanying consolidated financial statements
do not include any adjustments that might result from the outcome of these
uncertainties.

Malone & Bailey, PLLC
www.malone-bailey.com
Houston, Texas

May 17, 2004

<PAGE>


                             NANOSIGNAL CORPORATION
                   (FORMERLY KNOWN AS MICROSIGNAL CORPORATION)
                                 BALANCE SHEET
                               December 31, 2003

<TABLE>
<CAPTION>
                                        ASSETS
<S>                                                              <C>
Current assets
  Cash                                                           $   46,388
                                                                 ----------
    Total current assets                                             46,388

Property and equipment, net of accumulated
depreciation of   $278,908                                           21,194
                                                                 ----------
                                                                 $   67,582
                                                                 ----------
                                                                 ----------


                         LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:

  Accounts payable                                               $  137,741
  Accrued expenses                                                  138,292
  Lease payable                                                      38,650
  Accrued interest payable                                          935,403
  Notes payable                                                     615,339
  Notes payable - shareholders                                    2,042,251
  Deposits                                                           40,000
                                                                 ----------
    Total current liabilities                                     3,947,676
                                                                 ----------


STOCKHOLDERS' DEFICIT:

  Superpreferred common stock, $.001 par value,
   20,000,000 shares authorized, none issued
   and outstanding                                                        -
  Common stock, $.001 par value, 500,000,000
   shares authorized, 122,323,714 shares issued
   and outstanding                                                  122,324
  Additional paid in capital                                     14,655,042
  Accumulated deficit                                           (18,657,460)
                                                                 ----------
                                                                 (3,880,094)
                                                                 ----------
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                          67,582
                                                                 ----------
                                                                 ----------
</TABLE>
               See accompanying summary of accounting policies
                        and notes to financial statements.

<PAGE>

                             NANOSIGNAL CORPORATION
                   (FORMERLY KNOWN AS MICROSIGNAL CORPORATION)
                             STATEMENTS OF EXPENSES
                    For the Years Ended December 31, 2003 and 2002

<TABLE>
<CAPTION>
<S>                                         <C>                <C>
                                            2003               2002
                                            -------------      -------------
Operating Expenses:

  General, selling and administrative       $    876,945       $     84,617
Impairment                                     3,009,546                  -
  Consulting                                   9,707,050            312,500
                                            -------------      -------------

Loss from operations                         (13,593,541)          (397,117)

Interest expense                                 179,503            152,776
                                            -------------      -------------

Net loss                                    $(13,773,044)      $   (549,893)
                                            -------------      -------------
                                            -------------      -------------


Net loss per share:
  Net loss basic and diluted                $      (0.25)      $      (0.04)

Weighted average shares outstanding:

  Basic and diluted                           55,895,330         13,498,049
                                            -------------      -------------
                                            -------------      -------------

</TABLE>
               See accompanying summary of accounting policies
                        and notes to financial statements.

<PAGE>


                      NANOSIGNAL CORPORATION
                   (FORMERLY KNOWN AS MICROSIGNAL CORPORATION)
                         STATEMENT OF STOCKHOLDERS' DEFICIT
                           Years Ended December 31, 2003


<TABLE>
<CAPTION>
                                                                              Additional
                                               Common Stock                   paid in           Accumulated
                                        Shares              Amount            capital            deficit             Total
<S>                                     <C>                <C>                <C>                <C>                <C>
                                        -------------      -------------      -------------      -------------      -------------
Balance,
  December 31, 2001                       17,051,344       $     17,051      $   1,521,572     $    (4,334,523)     $ (2,795,900)

Issuance of common   stock for the
  net liabilities of Pro Glass
  Technologies,   Inc. and
  recapitalization                         4,395,336              4,395             (4,395)                  -                 -

Issuance of common
  stock for cash                             230,000                230             34,270                   -            34,500


Issuance of common
  stock for services                       2,412,500              2,413            359,462                   -           361,875

Net loss                                           -                  -                  -            (549,893)         (549,893)
                                        -------------      -------------      -------------      -------------      -------------

Balance,
  December 31, 2002                       24,089,180             24,089          1,910,909          (4,884,416)       (2,949,418)

Issuance of common
  stock for assets                        25,000,000             25,000          2,975,000                   -         3,000,000
Issuance of common
  stock for services                      73,234,534             73,235          9,769,133                   -         9,842,368

Net loss                                           -       $          -       $          -       $ (13,773,044      $(13,773,044)
                                        -------------      -------------      -------------      -------------      -------------

Balance,
  December 31, 2003                      122,323,714       $    122,324       $ 14,655,042       $ (18,657,460)     $ (3,880,094)
                                        -------------      -------------      -------------      -------------      -------------
                                        -------------      -------------      -------------      -------------      -------------

</TABLE>
               See accompanying summary of accounting policies
                        and notes to financial statements.

<PAGE>

                             NANOSIGNAL CORPORATION
                   (FORMERLY KNOWN AS MICROSIGNAL CORPORATION)
                         STATEMENTS OF CASH FLOWS
                    Years Ended December 31, 2003 and 2002


<TABLE>
<CAPTION>

                                           2003              2002
<S>                                       <C>                <C>
                                          -------------      -------------
CASH FLOWS FROM OPERATING ACTIVITIES

Net loss                                  $ (13,773,044)     $    (549,893)
Adjustments to reconcile net loss to

cash used by   operating activities:
  Common stock for services                   9,842,368            361,875
  Impairment                                  3,009,546
  Depreciation                                    8,109                  -
Net change in:
  Accounts payable                              126,741                  -
  Accrued interest payable                      179,503            152,776
                                          -------------      -------------

CASH FLOWS USED IN OPERATING ACTIVITIES        (606,777)           (35,242)
                                          -------------      -------------

CASH FLOWS FROM INVESTING ACTIVITES
  Capital expenditures                          (29,303)                 -
                                          -------------      -------------

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable                     680,501                  -
Proceeds form the sale of common stock                -             34,500
                                          -------------      -------------

CASH FLOWS PROVIDED BY FINANCING
ACTIVITIES                                      680,501             34,500
                                          -------------      -------------

NET DECREASE IN CASH                             44,421               (742)
Cash, beg. of period                              1,967              2,709
                                          -------------      -------------
Cash, end of period                       $      46,388      $       1,967
                                          -------------      -------------
                                          -------------      -------------

SUPPLEMENTAL CASH FLOW INFORMATION
  Interest paid                           $           -      $           -
  Income taxes paid                       $           -      $           -

NON-CASH TRANSACTIONS:
  Issuance of common stock for assets     $      12,490


</TABLE>
               See accompanying summary of accounting policies

                        and notes to financial statements.

<PAGE>

                     NANOSIGNAL CORPORATION
             (FORMERLY KNOWN AS MICROSIGNAL CORPORATION)

                 NOTES TO FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BUSINESS AND BASIS OF PRESENTATION
NanoSignal Corporation is a Pennsylvania corporation founded in November 1989
and is a Pittsburgh, Pennsylvania-based medical software development company
that specializes in developing software products for the radiology community.
In 2000, NanoSignal ceased its operations. Currently, NanoSignal is in the
process of restarting its operations and raising capital.

MANAGEMENT'S ESTIMATES AND ASSUMPTIONS
The accompanying financial statements are prepared in conformity with
accounting principles generally accepted in the United States of America which
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts
of revenue and expenses during the reporting period. Actual results could
differ from those estimates.

PROPERTY AND EQUIPMENT
Property and equipment are stated at cost. Depreciation is computed over the
estimated useful lives of the assets using the straight-line method for
financial reporting purposes and accelerated methods for income tax purposes.
Maintenance and repairs are charged to operations as incurred. NanoSignal
reviews property and equipment for impairment whenever events or changes in
circumstances indicate the carrying value of an asset may not be fully
recoverable.

REVENUE RECOGNITION
NanoSignal accounts for the licensing of software in accordance with American
Institute of Certified Public Accountants(AICPA) Statement of Position (SOP)
97-2, Software Revenue Recognition. NanoSignal recognizes revenue when
(i) persuasive evidence of an arrangement exists; (ii) delivery has occurred
or services have been rendered; (iii) the sales price is fixed or
determinable; and (iv) collectibility is reasonably assured. For software
arrangements with multiple elements, revenue is recognized dependent upon
whether vendor-specific objective evidence (VSOE) of fair value exists for
each of the elements. When VSOE does not exist for all the elements of a
software arrangement and the only undelivered element is post contract
customer support (PCS), the entire licensing fee is recognized ratably over
the contract period. Revenue attributable to undelivered elements, including
technical support is based on the average sales price of those elements when
sold separately, and is recognized ratably on a straight-line basis over the
products life cycle. PCS and subscription revenue is recognized ratably over
the contract period. Revenue from products licensed to original equipment
manufacturers (OEMs) is based on the licensing agreement with an OEM and
has historically been recognized when OEMs ship licensed products to their
customers. Provisions are recorded for estimated returns, concessions, and bad
debts.

COST OF REVENUE
Cost of revenue includes direct costs to manufacture and distribute product,
and direct costs to provide consulting, product support, training and
certification of system integrators.

INCOME TAXES
Deferred income taxes result from temporary differences between the financial
statement and income tax bases of assets and liabilities. NanoSignal adjusts
the deferred tax asset valuation allowance based on judgments as to future
realization of the deferred tax benefits supported by demonstrated trends in
NanoSignal's operating results.

<PAGE>

STOCK-BASED COMPENSATION
NanoSignal accounts for stock-based compensation issued to employees under
the intrinsic value method. Under this method, NanoSignal recognizes no
compensation expense for stock options granted when the number of underlying
shares is known and exercise price of the option is greater than or equal to
the fair market value of the stock on the date of grant. No options have been
granted.

NanoSignal accounts for non-cash stock-based compensation issued to non-
employees in accordance with the provisions of SFAS No. 123 and EITF No.
96-18, Accounting for Equity (deficit) Investments That Are Issued to Non-
Employees for Acquiring, or in Conjunction with Selling, Goods or Services.
Common stock issued to non-employees and consultants is based upon the value
of the services received or the quoted market price, whichever value is more
readily determinable.

LOSS PER COMMON SHARE
NanoSignal is required to provide basic and dilutive earnings (loss) per
common share information.

The basic net loss per common share is computed by dividing the net loss
applicable to common stockholders by the weighted average number of common
shares outstanding.

Diluted net loss per common share is computed by dividing the net loss
applicable to common stockholders, adjusted on an "as if converted" basis, by
the weighted average number of common shares outstanding plus potential
dilutive securities. For the years ended December 31, 2003 and 2002, potential
dilutive securities had an anti-dilutive effect and were not included in the
calculation of diluted net loss per common share.

RISKS AND UNCERTAINTIES
NanoSignal is subject to the business risks inherent in the medical software
development industry. These risks include, but are not limited to, a high
degree of competition within the medical software development industry and
continuous technological advances. Future technological advances in the
medical software development industry may result in the availability of new
services or products that could compete with the products and services
currently provided by NanoSignal or decreases in the cost of existing products
or services that could enable NanoSignal's established or potential customers
to fulfill their own needs for software products more cost efficiently. There
can be no assurance that NanoSignal would not be adversely affected in the
event of such technological change.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
NanoSignal does not expect the adoption of recently issued accounting
pronouncements to have a significant impact on NanoSignal's results of
operations, financial position or cash flow.

NOTE 2 - FINANCIAL CONDITION AND GOING CONCERN
For the years ended December 31, 2003 and 2002, NanoSignal incurred net
losses totaling $13,773,044 and $549,893, respectively, and at December 31,
2003 had negative working capital of $3,901,288. Because of these
recurring losses, NanoSignal will require additional working capital to
develop and support its technologies and business until NanoSignal either
(1) achieves a level of revenues adequate to generate sufficient cash flows
from operations; or (2) receives additional financing necessary to support
NanoSignal's working capital requirements.


Additionally, NanoSignal intends to raise additional working capital through
either private placements, public offerings and/or bank financing.

These conditions raise substantial doubt about NanoSignal's ability to
continue as a going concern. The consolidated financial statements do not
include any adjustments relating to the recoverability and classification
of asset carrying amounts or the amount and classification of liabilities
that might be necessary should NanoSignal be unable to continue as a going
concern.

<PAGE>

NOTE 3 - PATENT
The patent is designed to improve the quality and efficiency of magnetic
resonance imaging ("MRI") systems and barcode technology acquired in April
2003.  The patent was fully impaired as of December 31, 2003.

NOTE 4 - PROPERTY AND EQUIPMENT
At December 31, 2003, property and equipment consisted of the following:
                                            Useful
                                             Lives         Amount
     Computer and demo equipment              3-5         $ 278,360
     Furniture and fixtures                     7            21,742
                                                          ----------
                                                            300,102
     Less: accumulated depreciation and
     amortization                                           278,908
                                                          ----------
                                                          $  21,194
                                                          ----------
                                                          ----------

NOTE 5 - NOTES PAYABLE
NanoSignal has various notes with individuals, financial institutions and
shareholders. All of these notes are delinquent or due on demand as of
December 31, 2003. The notes bear interest at rates ranging from 8% to 16%
and are unsecured.

NOTE 6 - COMMON STOCK
On April 1, 2003, NanoSignal acquired 100% of the issued and outstanding
shares of Exxcode, Inc. of 25,000,000 shares of common stock valued at
$3,000,000. Exxcode has a proprietary bar code technology, which is used for
tracking medical records, x-rays and MRI's. The barcode can track NanoSignal's
technology.

During 2003, NanoSignal issued 73,234,534 shares of common stock for services
valued at 9,842,368.

NOTE 7 - INCOME TAXES
Deferred taxes are determined based on the temporary differences between the
financial statement and income tax bases of assets and liabilities as measured
by the enacted tax rates which will be in effect when these differences
reverse.

The components of deferred income tax assets (liabilities) at December 31,
2003, were as follows:
                                                             Amount
     Net operating loss carryforwards                     $ 3,466,000
     Valuation allowance                                   (3,466,000)
     Net deferred tax assets                                      $ -

At December 31, 2003, NanoSignal had a net operating loss carryforwards for
federal income tax purposes totaling approximately $10,195,150 which, if not
utilized, will expire in the years 2014 through 2023.

In September 2002, NanoSignal had a change in ownership, which has resulted
in NanoSignal's net operating loss carryforwards being subject to certain
utilization limitations in the future under Internal Revenue Code Section 382.

NOTE 8 - COMMITMENTS
NanoSignal entered into a lease in October 2002 for office space located in
Pittsburgh, Pennsylvania on a three year lease term through September 2005.
This lease was cancelled in April 2004 and no future payments were necessary.
The monthly rental payment was $1,854 per month. NanoSignal now has a month
to month office lease in Las Vegas, Nevada. They are currently under
negotiations to create a written lease.

Rent expense for the years ended December 31, 2003 and 2002 totaled $20,490
and $3,706 respectively.

<PAGE>

EMPLOYMENT AGREEMENTS
Effective December 1, 2003 NanoSignal entered into an employment agreement
with its President and Chief Operating Officer.  The agreement provides for
an annual salary of $240,000 for each year, plus incentives and certain
employee benefits, as defined by the agreement.  The agreement shall
terminate on November 17, 2005.

NOTE 9 - SUBSEQUENT EVENT
In March 2004 NanaSignal changed the authorized shares of Common Stock from
300,000,000 to 500,000,000 and changed the Superpreferred Common Stock from
20,000,000 to 50,000,000. The Superpreferred Common Stock has voting rights
of ten votes per each one share of Superpreferred Common Stock.

Effective February 2, 2004 NanoSignal entered into an employment agreement
with its Chief Executive Officer.  The one year agreement provides for an
annual salary of $182,500 for each year, plus incentives and certain employee
benefits, as defined by the agreement.  The agreement also provides for
5,000,000 shares of common stock.

In April 2004, NanoSignal entered into a settlement agreement with a former
officer of the Company and agreed to issue 28,000,000 shares of common stock
and pay a commission fee of 10% for his referrals.



List of Exhibits

The following exhibits are filed with this report. Financial Statements.

(b) There were no Reports filed on Form 8-K during the fourth quarter of the
Company's fiscal year ended December 31, 2003.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.



May 28, 2004                 NANOSIGNAL CORPORATION




                               /s/Dr. Lawrence Madoff
                               --------------------------------
                               Dr. Lawrence Madoff, President, Director




May 28, 2004                 /s/ Dr. Lawrence Madoff
                               --------------------------------
                               Dr. Lawrence Madoff, President, Director